Martin Auster
Stock Analyst at Raymond James
(2.65)
# 1,981
Out of 5,128 analysts
55
Total ratings
58.14%
Success rate
13.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SEPN Septerna | Initiates: Strong Buy | $38 | $26.41 | +43.88% | 1 | Dec 19, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $74.27 | -4.40% | 2 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | n/a | $72.37 | - | 2 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $80.94 | +33.43% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $213.28 | +27.06% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $19.39 | +80.51% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $422.50 | +0.36% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $61.31 | +95.73% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $24.20 | +333.88% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $9.98 | +160.52% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $5.61 | +2,039.04% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $725 → $300 | $21.00 | +1,328.57% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $35.17 | +64.91% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $503.69 | -61.09% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $1.18 | +8,205.08% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $176.00 | -65.91% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $44.23 | +46.96% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $23.46 | +211.17% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $23.08 | +237.95% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.84 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $9.97 | +331.29% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $10.13 | +107.31% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $45.21 | -64.61% | 1 | May 7, 2020 |
Septerna
Dec 19, 2025
Initiates: Strong Buy
Price Target: $38
Current: $26.41
Upside: +43.88%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $74.27
Upside: -4.40%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $72.37
Upside: -
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $80.94
Upside: +33.43%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $213.28
Upside: +27.06%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $19.39
Upside: +80.51%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $422.50
Upside: +0.36%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $61.31
Upside: +95.73%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $24.20
Upside: +333.88%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $9.98
Upside: +160.52%
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $5.61
Upside: +2,039.04%
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $21.00
Upside: +1,328.57%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $35.17
Upside: +64.91%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $503.69
Upside: -61.09%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.18
Upside: +8,205.08%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $176.00
Upside: -65.91%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $44.23
Upside: +46.96%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $23.46
Upside: +211.17%
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $23.08
Upside: +237.95%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $3.84
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $9.97
Upside: +331.29%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $10.13
Upside: +107.31%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $45.21
Upside: -64.61%